ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BCEL Atreca Inc

0.15
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Atreca Inc NASDAQ:BCEL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.15 0.16 0.17 0 01:00:00

Atreca Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference

12/05/2020 9:30pm

GlobeNewswire Inc.


Atreca (NASDAQ:BCEL)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Atreca Charts.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on Tuesday, May 19, at 11:30 a.m. EDT.

A live audio webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of the webcast will be available on the Company's website for 90 days following the live presentation.

About Atreca, Inc. Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

ContactsAtreca, Inc. Herb Cross Chief Financial Officer info@atreca.com Investors: Alex Gray, 650-779-9251 agray@atreca.com

Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com

Source: Atreca, Inc.

1 Year Atreca Chart

1 Year Atreca Chart

1 Month Atreca Chart

1 Month Atreca Chart